Affinage

FSCN1

Fascin · UniProt Q16658

Length
493 aa
Mass
54.5 kDa
Annotated
2026-06-09
100 papers in source corpus 24 papers cited in narrative 24 extracted findings
Cross-family judge vs UniProt: Affinage preferred faithfulness: 6/6 claims corpus-supported (100%)

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

FSCN1 (Fascin-1) is an actin-organizing protein that drives cell migration, invasion, and metastasis by promoting filopodia, lamellipodia, and focal adhesion dynamics, a role demonstrated directly by CRISPR knockout and pharmacological inhibition that collapse these cytoskeletal structures and block invasion in vivo (PMID:36971100). Beyond bundling actin, it acts as a molecular linker between TGF-β family type I receptors and actin filaments, where its loss traps internalized receptors in clathrin-coated vesicles, prevents their trafficking to early endosomes, and attenuates Nodal signaling and endoderm formation (PMID:27545838). In epithelial contexts FSCN1 promotes epithelial-to-mesenchymal transition by negatively regulating E-cadherin and by physically interacting with and stabilizing the transcription factor Snail1 (PMID:34494554, PMID:30231243). FSCN1 also exerts non-canonical RNA-binding activity, binding PTK6 pre-mRNA to suppress PTK6 and drive tumor progression through AKT/GSK3β signaling (PMID:35401239). Its expression is controlled at multiple layers: transcriptionally by GRHL3, SNAI2, β-catenin, and the nucleolar protein LYAR (PMID:34494554, PMID:28488774, PMID:36971100, PMID:35069968), and by KDM7A-mediated histone demethylation at its promoter in neurons, where it supports dendritic spine density and morphine reward memory (PMID:39836528); at the mRNA level by HuR-dependent stabilization, METTL14/IGF2BP3-mediated m6A modification, and direct 3'UTR targeting by miR-145 and miR-133a/b (PMID:34733789, PMID:38679464, PMID:21351259); and at the protein level by binding partners SYTL2 and NQO1 that protect it from proteasomal degradation (PMID:37147713, PMID:37424815). Small-molecule inhibition of its actin-bundling activity (NP-G2-044/G2-044) suppresses cancer invasion and pathological angiogenesis in vivo (PMID:36971100, PMID:37596693).

Mechanistic history

Synthesis pass · year-by-year structured walk · 14 steps
  1. 2005 Low

    Established a link between FSCN1 expression and neuronal differentiation, framing its actin-bundling role in growth cone/neurite formation.

    Evidence CBP siRNA depletion and retinoic acid differentiation in NT2 neuronal precursor cells with microarray/qPCR readout

    PMID:15882811

    Open questions at the time
    • No direct CBP promoter binding shown
    • Functional role in neurite formation inferred from expression, not tested
  2. 2010 Medium

    Defined post-transcriptional control of FSCN1 by identifying direct miRNA targeting of its 3'UTR, explaining how FSCN1 is silenced in non-invasive states.

    Evidence Luciferase reporter mapping of miR-145 and miR-133a/b 3'UTR sites plus FSCN1 knockdown invasion assays in esophageal cancer

    PMID:21351259

    Open questions at the time
    • Does not address protein-level or transcriptional regulation
    • Endogenous miRNA dosage effects not quantified
  3. 2016 High

    Revealed a non-bundling, trafficking function: FSCN1 links TGF-β family type I receptors to actin to route them from clathrin-coated vesicles to early endosomes, controlling Nodal signaling.

    Evidence Reciprocal Co-IP, zebrafish knockdown/knockout, confocal receptor-trafficking imaging, genetic epistasis with Nodal

    PMID:27545838

    Open questions at the time
    • Whether mammalian FSCN1 performs the identical trafficking step is untested
    • Structural basis of receptor-FSCN1 binding unresolved
  4. 2017 Medium

    Connected upstream signaling and transcription factors to FSCN1 induction, showing EGF/MAPK and SNAI2 drive its expression to promote migration and EMT.

    Evidence MAPK pathway inhibition with EGF stimulation in TNBC cells; luciferase mapping of SNAI2 binding to FSCN1 promoter in HNSC

    PMID:28488774 PMID:29142206

    Open questions at the time
    • Direct vs indirect MAPK regulation not separated
    • Single-lab promoter reporter without endogenous ChIP for SNAI2
  5. 2018 Medium

    Placed FSCN1 within EMT and drug-resistance circuitry by showing it stabilizes Snail1, sits within the Twist/EMT axis, and lies downstream of PI3K/AKT/GSK-3β.

    Evidence Co-IP with Snail1 and functional EMT assays in ovarian cancer; Twist epistasis in DOX-resistant HCC; kinase inhibitor/GSK-3β knockdown in RCC with xenografts

    PMID:29148041 PMID:29568938 PMID:30231243

    Open questions at the time
    • Mechanism of Snail1 stabilization by FSCN1 not defined
    • Direct vs indirect kinase regulation not resolved
  6. 2019 High

    Defined the GRHL3→FSCN1→E-cadherin axis in collective epithelial migration, extending FSCN1 function beyond cancer to physiological wound healing.

    Evidence ATAC-seq for GRHL3-motif accessibility, Grhl3 conditional knockout mice, wound-healing and E-cadherin analysis

    PMID:34494554

    Open questions at the time
    • Direct GRHL3 binding to FSCN1 locus not shown by ChIP
    • How FSCN1 mechanistically relaxes adherens junctions unclear
  7. 2019 Medium

    Mapped the FSCN1 protein interactome, nominating filopodium-assembly, GTPase, adhesion, and metabolic partners as candidate effectors.

    Evidence Co-IP/mass spectrometry in laryngeal carcinoma cell lines with western/IF validation of AIMP1 and LTA4H

    PMID:31287215 PMID:31298480

    Open questions at the time
    • Functional consequences of individual interactions not reconstituted
    • Interactome from single cancer type
  8. 2021 Medium

    Added a transcriptional and mRNA-stability layer to FSCN1 control via the nucleolar factor LYAR and the lncRNA/HuR axis, linking FSCN1 to fatty acid synthesis and AKT activation.

    Evidence ChIP/reporter assays for LYAR in colorectal cancer; RNA pull-down/RIP/stability assays for ADORA2A-AS1–HuR–FSCN1 in HCC with xenografts

    PMID:34733789 PMID:35069968

    Open questions at the time
    • Mechanism linking FSCN1 to FASN/SCD not defined
    • Single-lab findings per axis
  9. 2022 Medium

    Extended FSCN1 signaling to the tumor microenvironment, showing it binds IGF-1R to drive PI3K-AKT/JAK-STAT activation and macrophage M2 polarization.

    Evidence Co-IP, Seahorse metabolic analysis, cytokine qRT-PCR, and in vivo imaging in lung adenocarcinoma

    PMID:36223033

    Open questions at the time
    • Single Co-IP without reciprocal validation
    • Direct vs adaptor role of FSCN1 at IGF-1R unclear
  10. 2023 Medium

    Identified a non-canonical RNA-binding function and protein-level stabilizers, broadening FSCN1's mechanism beyond cytoskeletal bundling.

    Evidence RIP showing FSCN1 binding to PTK6 pre-mRNA in esophageal cancer; Co-IP/stability assays for SYTL2 and NQO1 with in vivo rescue in prostate and arsenic-transformed lung cells

    PMID:35401239 PMID:37147713 PMID:37424815

    Open questions at the time
    • RNA-binding domain/motif of FSCN1 not mapped
    • How SYTL2/NQO1 block FSCN1 ubiquitination not defined
  11. 2023 High

    Validated FSCN1 as a pharmacological target downstream of β-catenin, with small-molecule inhibition collapsing cytoskeletal structures and suppressing invasion and pathological angiogenesis.

    Evidence CRISPR KO plus G2-044 inhibitor and zebrafish metastasis model; NP-G2-044 in endothelial assays and OIR/CNV mouse models

    PMID:36971100 PMID:37596693

    Open questions at the time
    • Inhibitor selectivity over fascin paralogs not addressed in timeline
    • Angiogenesis interaction partners not fully defined
  12. 2023 High

    Connected acetylation-controlled splicing to Fscn1 expression, showing a p300→SF3A2(K10)→Fscn1 splicing axis with a cardioprotective, mitochondrial-respiration outcome.

    Evidence Acetylomic proteomics, SPR/CETSA binding kinetics, site-specific mutagenesis, and Seahorse in cardiomyocytes treated with ginsenoside Rb2

    PMID:38101749

    Open questions at the time
    • Which Fscn1 isoform mediates mitochondrial protection not specified
    • Direct role of FSCN1 protein in respiration mechanism unresolved
  13. 2024 Medium

    Established m6A-dependent stabilization of FSCN1 mRNA by viral oncogenes, adding epitranscriptomic regulation to its control.

    Evidence HPV16 E6/E7 and METTL14/IGF2BP3 knockdown with rescue in cervical carcinoma cells

    PMID:38679464

    Open questions at the time
    • m6A site on FSCN1 mRNA not mapped
    • Single-lab study
  14. 2025 Medium

    Demonstrated an epigenetic-neuronal role: KDM7A demethylation activates Fscn1 to support dendritic spine density and drug-reward memory, extending FSCN1 function into CNS plasticity.

    Evidence Locus-specific H3K9me2/H3K27me2 ChIP, viral Fscn1 knockdown, spine morphology, and conditioned place preference behavior in mPFC neurons

    PMID:39836528

    Open questions at the time
    • How actin-bundling drives spine density mechanistically not dissected
    • KDM7A binding to Fscn1 promoter inferred from demethylation only

Open questions

Synthesis pass · forward-looking unresolved questions
  • How FSCN1's distinct activities — actin bundling, receptor trafficking, RNA binding, and partner-controlled stability — are coordinated within a single cell and whether they share a common structural determinant remains unresolved.
  • No structural model integrating actin-bundling and RNA-binding functions
  • Regulatory hierarchy among transcriptional, m6A, miRNA, and protein-stability controls not established
  • Tissue-specific selection among FSCN1's functions unknown

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0008092 cytoskeletal protein binding 3 GO:0003723 RNA binding 1 GO:0060090 molecular adaptor activity 1
Localization
GO:0005856 cytoskeleton 2 GO:0005829 cytosol 1
Pathway
R-HSA-162582 Signal Transduction 3 R-HSA-1266738 Developmental Biology 2 R-HSA-1643685 Disease 2 R-HSA-9609507 Protein localization 1
Partners
AIMP1HURIGF1RLTA4HNQO1SNAI1SYTL2TGFBR1

Evidence

Reading pass · 24 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
2016 Zebrafish Fscn1a specifically interacts with TGF-β family type I receptors; its depletion disrupts the association between receptors and actin filaments, sequesters internalized receptors into clathrin-coated vesicles, and prevents their trafficking to early endosomes, thereby reducing Nodal signal transduction and endoderm formation. Fscn1 acts as a molecular linker between TGF-β family type I receptors and actin filaments. Co-immunoprecipitation, knockdown/knockout in zebrafish embryos, confocal imaging of receptor trafficking, genetic epistasis with Nodal signaling Nature communications High 27545838
2019 GRHL3 transcription factor directly activates FSCN1 expression in wound-front keratinocytes (ATAC-seq shows wound-induced chromatin accessibility near Fscn1 enriched for GRHL3 motifs). FSCN1 acts as a negative regulator of E-cadherin, relaxing keratinocyte-keratinocyte adherens junctions to promote collective migration and wound closure. Grhl3-cKO mice have reduced Fscn1 expression and impaired wound-front migration. ATAC-seq on wounded keratinocytes, conditional knockout mice (Grhl3-cKO), wound-healing assays, E-cadherin expression analysis, in vivo wound closure measurements JCI insight High 34494554
2019 FSCN1 physically interacts with AIMP1 and LTA4H in laryngeal squamous cell carcinoma cells, as identified by co-immunoprecipitation/mass spectrometry and validated by co-IP/western blotting and immunofluorescence co-localization. FSCN1-binding proteins are enriched in filopodium assembly-regulation and GTPase activity pathways. Co-immunoprecipitation followed by mass spectrometry, co-IP/western blot validation, immunofluorescence co-localization Proteomics Medium 31287215
2019 Mass spectrometry-based interactome of FSCN1 in LSCC cells identified 119 interacting proteins enriched in cell adhesion, glycolysis/gluconeogenesis, protein ubiquitination regulation, and rRNA processing pathways. Immunoprecipitation followed by mass spectrometry in two LSCC cell lines (Hep-2, TU-177) IUBMB life Low 31298480
2018 FSCN1 physically interacts with Snail1 (Co-IP) and increases Snail1 protein levels in ovarian cancer cells, thereby promoting EMT (loss of E-cadherin, gain of vimentin). FSCN1 overexpression or depletion correspondingly modulates Snail1 and EMT markers. Co-immunoprecipitation, western blotting, RT-qPCR, transwell invasion assay, overexpression/knockdown in EOC cells Cellular physiology and biochemistry Medium 30231243
2017 EGF induces FSCN1 expression through activation of the MAPK pathway in triple-negative breast cancer cells, and elevated FSCN1 promotes cell migration and invasion. siRNA knockdown, western blotting, EGF stimulation with MAPK pathway inhibitors, migration/invasion assays Scientific reports Medium 29142206
2018 FSCN1 knockdown in doxorubicin-resistant HCC cells reduces drug resistance and is accompanied by decreased vimentin and increased E-cadherin, indicating FSCN1 promotes DOX resistance via EMT promotion. When EMT was suppressed by Twist knockdown, FSCN1 expression no longer affected DOX sensitivity, placing FSCN1 upstream of or within the Twist/EMT axis for resistance. siRNA knockdown, EMT marker western blotting, drug sensitivity assays, Twist knockdown epistasis experiment, hypoxia model International journal of oncology Medium 29568938
2021 ADORA2A-AS1 (lncRNA) competitively binds HuR (RNA-binding protein), preventing HuR from binding to FSCN1 mRNA and thereby decreasing FSCN1 transcript stability and expression. Reduced FSCN1 suppresses AKT pathway activation in HCC. Functional rescue assays show blockade of the FSCN1/AKT axis abrogates ADORA2A-AS1's tumor-suppressive effects. RNA pull-down, RNA immunoprecipitation, RNA stability assay, western blotting, qRT-PCR, xenograft models Frontiers in oncology Medium 34733789
2021 LYAR (nucleolar protein) transcriptionally upregulates FSCN1 expression in colorectal cancer cells, as demonstrated by ChIP assay, gene reporter assay, and rescue experiments. FSCN1 knockdown inhibits subcutaneous tumorigenesis and downregulates FASN and SCD (fatty acid synthesis enzymes), linking FSCN1 to fatty acid metabolism. ChIP assay, luciferase reporter assay, microarray, rescue experiments, xenograft tumor model Oxidative medicine and cellular longevity Medium 35069968
2017 SNAI2 directly binds a site in the FSCN1 promoter (verified by luciferase reporter assay) and its overexpression increases FSCN1 mRNA and protein in HNSC cells. FSCN1 overexpression reduces E-cadherin and Claudin-1 and increases Vimentin and N-cadherin, promoting EMT. Luciferase reporter assay, overexpression experiments, western blotting for EMT markers Cell biology international Medium 28488774
2022 FSCN1 binds to IGF-1R in lung adenocarcinoma cells (co-immunoprecipitation), activating PI3K-AKT and JAK-STAT signaling pathways, which promotes secretion of IL4 and M-CSF, inducing M2 polarization of macrophages via PTPRF upregulation. Co-immunoprecipitation, Seahorse metabolic analysis, western blotting, qRT-PCR, IVIS in vivo imaging Cellular oncology Medium 36223033
2023 FSCN1 binds to the pre-mRNA of PTK6 as an RNA-binding protein (RNA immunoprecipitation), downregulating PTK6 mRNA and protein levels to promote esophageal cancer progression via the AKT/GSK3β signaling pathway. A specific PTK6-T2 peptide blocks this FSCN1-pre-mRNA binding and reverses FSCN1's tumor-promoting effect. RNA immunoprecipitation, whole-genome expression sequencing, in vitro and in vivo tumor experiments Frontiers in pharmacology Medium 35401239
2023 SYTL2 binds FSCN1 protein (co-immunoprecipitation) and inhibits its proteasome-mediated degradation, enhancing FSCN1 protein stability and thereby increasing pseudopodia formation and prostate cancer cell invasion/lymph node metastasis in vivo. FSCN1 knockdown rescues/reverses the oncogenic effect of SYTL2. Co-immunoprecipitation, protein stability assay, 3D migration model, popliteal lymph node metastasis in vivo model, rescue experiments Journal of translational medicine Medium 37147713
2023 NQO1 directly binds FSCN1 protein (immunoprecipitation) and stabilizes FSCN1, increasing migration and invasion in arsenic-transformed lung cells. Knockdown of MEG3 lncRNA upregulates NQO1, which stabilizes FSCN1; NQO1 knockdown reduces FSCN1-dependent migration/invasion, effects reversed by FSCN1 overexpression. Immunoprecipitation, western blotting, migration/invasion assays, rescue/epistasis experiments with MEG3, NQO1, FSCN1 American journal of cancer research Medium 37424815
2023 FSCN1 is a transcriptional target of β-catenin in ACC cells; FSCN1 inactivation (CRISPR/Cas9 KO or inhibitor G2-044) reduces filopodia, lamellipodia/ruffles, and focal adhesions, decreases cell invasion in Matrigel, and reduces metastasis formation in a zebrafish in vivo model. CRISPR/Cas9 knockout, pharmacological inhibition (G2-044), reporter assay for β-catenin binding, filopodia/focal adhesion imaging, zebrafish metastasis model International journal of cancer High 36971100
2023 Oral small-molecule FSCN1 inhibitor NP-G2-044 impedes sprouting, migration, and filopodia formation in cultured endothelial cells and suppresses pathological ocular neovascularization (OIR and CNV mouse models) in vivo. Co-IP experiments reveal a mechanistic interaction between FSCN1 and angiogenesis-related factors. Transwell/wound scratch/tube formation/3D bead sprouting assays, rhodamine-phalloidin staining, in vivo OIR and CNV mouse models, pharmacokinetic HPLC-MS/MS, Co-IP Journal of translational medicine Medium 37596693
2023 Ginsenoside Rb2 inhibits p300 acetyltransferase activity (thermodynamic, kinetic, and enzymatic experiments), reducing p300-mediated acetylation of spliceosome protein SF3A2 at lysine 10, which promotes alternative splicing of Fscn1 and upregulates Fscn1 expression, enhancing mitochondrial respiration to protect cardiomyocytes against ischemic injury. 4D-label-free acetylomic analysis, co-immunoprecipitation, immunofluorescent staining, mitochondrial respiration (Seahorse), RNA-seq, site-specific mutation, shRNA interference, cellular thermal shift assay, surface plasmon resonance Journal of advanced research High 38101749
2024 HPV16 E6/E7 oncogenes upregulate METTL14 and IGF2BP3, which mediate N6-methyladenosine (m6A) modification on FSCN1 mRNA to stabilize it and increase FSCN1 protein expression in cervical squamous cell carcinoma. Knockdown of E6/E7 or METTL14/IGF2BP3 suppresses FSCN1 expression and cancer cell proliferation/migration, effects reversed by FSCN1 overexpression. qRT-PCR, western blotting, MTT assay, flow cytometry, wound healing assay, tumor formation assay, gain/loss-of-function experiments Clinical and experimental pharmacology & physiology Medium 38679464
2018 FSCN1 promotes RCC cell invasion in vitro and metastasis in vivo; its expression is regulated by the PI3K/AKT/GSK-3β pathway (PI3K/AKT inhibitors or GSK-3β knockdown decrease FSCN1 expression). FSCN1 overexpression upregulates MMP9 and N-cadherin. PI3K/AKT inhibitor treatment, GSK-3β siRNA knockdown, western blotting, Matrigel invasion assay, orthotopic xenograft mice model Journal of cellular physiology Medium 29148041
2015 FSCN1 loss-of-function (siRNA) suppresses migration and invasion of pituitary adenoma GH3 cells, accompanied by downregulation of Notch1 and DLL3 expression, suggesting FSCN1 acts upstream of Notch signaling in pituitary adenoma invasion. siRNA knockdown, transwell invasion assay, western blotting for Notch1/DLL3 Molecular and cellular endocrinology Low 26522130
2025 KDM7A demethylase reduces H3K9me2 and H3K27me2 enrichment at the Fscn1 promoter in medial prefrontal cortex neurons, thereby increasing Fscn1 transcription. Fscn1 knockdown in the mPFC reduces dendritic spine density, neuronal activity, and morphine-conditioned place preference memory consolidation, phenocopying Kdm7a knockdown. Nanopore direct RNA sequencing, H3K9me2/H3K27me2 ChIP at Fscn1 promoter, viral Fscn1 knockdown, dendritic spine analysis (morphology), behavioral CPP assay Advanced science Medium 39836528
2005 FSCN1 expression in NT2 neuronal precursor cells is regulated by CBP (CREB-binding protein): siRNA depletion of CBP reduces FSCN1 mRNA and protein. FSCN1 is upregulated during retinoic acid-induced neuronal differentiation of NT2 cells, suggesting a role in neurite/growth cone formation consistent with its actin-bundling function. RNA interference (CBP siRNA), cDNA microarray, RT-qPCR, western blotting, retinoic acid differentiation model Neuroscience letters Low 15882811
2010 miR-145, miR-133a, and miR-133b directly regulate FSCN1 by binding conserved sequences in the 3'UTR (luciferase reporter assay confirms two miR-145 target sites and one miR-133a/b site). FSCN1 loss-of-function inhibits esophageal squamous cell carcinoma cell growth and invasion. Luciferase reporter assay, gain-of-function miRNA transfection, siRNA FSCN1 knockdown, cell proliferation and invasion assays International journal of cancer Medium 21351259
2021 circFSCN1 (circular RNA from the FSCN1 locus) is highly expressed in the cytoplasm of mature dendritic cells; knockdown of circFSCN1 arrests DCs at an immature state, impairing their ability to activate T cells and enhancing regulatory T cell generation, preventing allograft rejection in a mouse heart transplantation model. circFSCN1 siRNA knockdown in bone marrow-derived DCs, flow cytometry for DC maturation, mixed lymphocyte reactions, in situ RNA hybridization, heterotopic allogeneic murine heart transplantation The Journal of heart and lung transplantation Low 34052126

Source papers

Stage 0 corpus · 100 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
2010 miR-145, miR-133a and miR-133b: Tumor-suppressive miRNAs target FSCN1 in esophageal squamous cell carcinoma. International journal of cancer 409 21351259
2010 miR-145 and miR-133a function as tumour suppressors and directly regulate FSCN1 expression in bladder cancer. British journal of cancer 306 20160723
2015 Long non-coding RNA urothelial cancer-associated 1 promotes bladder cancer cell migration and invasion by way of the hsa-miR-145-ZEB1/2-FSCN1 pathway. Cancer science 162 26544536
2011 Restoration of miR-145 expression suppresses cell proliferation, migration and invasion in prostate cancer by targeting FSCN1. International journal of oncology 137 21258769
2019 Targeting YAP1/LINC00152/FSCN1 Signaling Axis Prevents the Progression of Colorectal Cancer. Advanced science (Weinheim, Baden-Wurttemberg, Germany) 134 32042551
2018 Promoter Methylation-Regulated miR-145-5p Inhibits Laryngeal Squamous Cell Carcinoma Progression by Targeting FSCN1. Molecular therapy : the journal of the American Society of Gene Therapy 100 30341010
2013 MicroRNA-133a regulates the mRNAs of two invadopodia-related proteins, FSCN1 and MMP14, in esophageal cancer. British journal of cancer 95 24196787
2017 Long non-coding RNA PCAT-1 contributes to tumorigenesis by regulating FSCN1 via miR-145-5p in prostate cancer. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 81 28922730
1999 Protein transport and flagellum assembly dynamics revealed by analysis of the paralysed trypanosome mutant snl-1. Journal of cell science 81 10523512
2019 Down-regulation of long noncoding RNA PVT1 inhibits esophageal carcinoma cell migration and invasion and promotes cell apoptosis via microRNA-145-mediated inhibition of FSCN1. Molecular oncology 62 31369196
2016 miR-429 functions as a tumor suppressor by targeting FSCN1 in gastric cancer cells. OncoTargets and therapy 61 27042104
2016 miR-145 suppresses breast cancer cell migration by targeting FSCN-1 and inhibiting epithelial-mesenchymal transition. American journal of translational research 59 27508031
2019 Long non-coding RNA ZEB1-AS1 regulates miR-200b/FSCN1 signaling and enhances migration and invasion induced by TGF-β1 in bladder cancer cells. Journal of experimental & clinical cancer research : CR 55 30823924
2020 Knockdown of lncRNA CCAT1 enhances sensitivity of paclitaxel in prostate cancer via regulating miR-24-3p and FSCN1. Cancer biology & therapy 49 32089062
2021 Exosomal lncRNA LINC01711 facilitates metastasis of esophageal squamous cell carcinoma via the miR-326/FSCN1 axis. Aging 46 34370713
2013 miR-133a functions as a tumor suppressor and directly targets FSCN1 in pancreatic cancer. Oncology research 45 25198665
2017 EGFR conjunct FSCN1 as a Novel Therapeutic Strategy in Triple-Negative Breast Cancer. Scientific reports 44 29142206
2018 FSCN‑1 increases doxorubicin resistance in hepatocellular carcinoma through promotion of epithelial-mesenchymal transition. International journal of oncology 42 29568938
2014 The role of microRNA-133b and its target gene FSCN1 in gastric cancer. Journal of experimental & clinical cancer research : CR 42 25433493
2017 FSCN1 gene polymorphisms: biomarkers for the development and progression of breast cancer. Scientific reports 41 29162880
2015 MiR-24 functions as a tumor suppressor in nasopharyngeal carcinoma through targeting FSCN1. Journal of experimental & clinical cancer research : CR 41 26503504
2017 miR-539 inhibits FSCN1 expression and suppresses hepatocellular carcinoma migration and invasion. Oncology reports 38 28393215
2020 SOX2 Promotes Brain Metastasis of Breast Cancer by Upregulating the Expression of FSCN1 and HBEGF. Molecular therapy oncolytics 37 32322668
1998 C-terminal tripeptide Ser-Asn-Leu (SNL) of human D-aspartate oxidase is a functional peroxisome-targeting signal. The Biochemical journal 37 9820813
2018 LincRNA-ROR promotes metastasis and invasion of esophageal squamous cell carcinoma by regulating miR-145/FSCN1. OncoTargets and therapy 36 29430188
2016 miR-200b inhibits migration and invasion in non-small cell lung cancer cells via targeting FSCN1. Molecular medicine reports 36 27356635
2017 20(S)-Rg3 blocked epithelial-mesenchymal transition through DNMT3A/miR-145/FSCN1 in ovarian cancer. Oncotarget 35 28881818
2010 Electroacupuncture versus celecoxib for neuropathic pain in rat SNL model. Neuroscience 35 20654703
2023 Electroacupuncture alleviates neuropathic pain caused by SNL by promoting M2 microglia polarization through PD-L1. International immunopharmacology 33 37573685
2022 FSCN1 acts as a promising therapeutic target in the blockade of tumor cell motility: a review of its function, mechanism, and clinical significance. Journal of Cancer 33 35711849
2018 FSCN1 Promotes Epithelial-Mesenchymal Transition Through Increasing Snail1 in Ovarian Cancer Cells. Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology 31 30231243
2016 Fscn1 is required for the trafficking of TGF-β family type I receptors during endoderm formation. Nature communications 31 27545838
2015 Reverse Correlation between MicroRNA-145 and FSCN1 Affecting Gastric Cancer Migration and Invasion. PloS one 31 26010149
2015 MicroRNA-145 inhibits migration and invasion by down-regulating FSCN1 in lung cancer. International journal of clinical and experimental medicine 31 26309531
2015 The role of FSCN1 in migration and invasion of pituitary adenomas. Molecular and cellular endocrinology 31 26522130
2015 MicroRNA-145 and MicroRNA-133a Inhibited Proliferation, Migration, and Invasion, While Promoted Apoptosis in Hepatocellular Carcinoma Cells Via Targeting FSCN1. Digestive diseases and sciences 29 26173501
2021 Electroacupuncture improves neuronal plasticity through the A2AR/cAMP/PKA signaling pathway in SNL rats. Neurochemistry international 27 33577869
2021 LYAR Promotes Colorectal Cancer Progression by Upregulating FSCN1 Expression and Fatty Acid Metabolism. Oxidative medicine and cellular longevity 27 35069968
2019 miR-145 Contributes to the Progression of Cervical Carcinoma by Directly Regulating FSCN1. Cell transplantation 27 31271056
2022 LncRNA CRNDE promotes cell proliferation, migration and invasion of ovarian cancer via miR-423-5p/FSCN1 axis. Molecular and cellular biochemistry 26 35166986
2019 MicroRNA-145 regulates immune cytokines via targeting FSCN1 in Staphylococcus aureus-induced mastitis in dairy cows. Reproduction in domestic animals = Zuchthygiene 26 30974481
2023 Ginsenoside Rb2 inhibits p300-mediated SF3A2 acetylation at lysine 10 to promote Fscn1 alternative splicing against myocardial ischemic/reperfusion injury. Journal of advanced research 25 38101749
2021 GRHL3 activates FSCN1 to relax cell-cell adhesions between migrating keratinocytes during wound reepithelialization. JCI insight 23 34494554
2020 MicroRNA-488 inhibits proliferation and motility of tumor cells via downregulating FSCN1, modulated by Notch3 in breast carcinomas. Cell death & disease 23 33099573
2015 The clinical significance of FSCN1 in non-small cell lung cancer. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 23 26211585
2021 ADORA2A-AS1 Restricts Hepatocellular Carcinoma Progression via Binding HuR and Repressing FSCN1/AKT Axis. Frontiers in oncology 22 34733789
2005 Minor expression of fascin-1 gene (FSCN1) in NTera2 cells depleted of CREB-binding protein. Neuroscience letters 22 15882811
2017 FSCN1 is upregulated by SNAI2 and promotes epithelial to mesenchymal transition in head and neck squamous cell carcinoma. Cell biology international 21 28488774
2017 XIAP 3'-untranslated region as a ceRNA promotes FSCN1 function in inducing the progression of breast cancer by binding endogenous miR-29a-5p. Oncotarget 20 28186968
2021 Preventing alloimmune rejection using circular RNA FSCN1-silenced dendritic cells in heart transplantation. The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation 19 34052126
2019 Mass Spectrometric Analysis Identifies AIMP1 and LTA4H as FSCN1-Binding Proteins in Laryngeal Squamous Cell Carcinoma. Proteomics 18 31287215
2022 Translocator Protein (TSPO) Alleviates Neuropathic Pain by Activating Spinal Autophagy and Nuclear SIRT1/PGC-1α Signaling in a Rat L5 SNL Model. Journal of pain research 17 35356265
2021 LncRNA LOC146880 promotes esophageal squamous cell carcinoma progression via miR-328-5p/FSCN1/MAPK axis. Aging 17 34016787
2019 Mass spectrometry-based proteomic analysis of FSCN1-interacting proteins in laryngeal squamous cell carcinoma cells. IUBMB life 17 31298480
2016 Significance of BMI1 and FSCN1 expression in colorectal cancer. Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology Association 17 27488323
2016 MicroRNA-133b inhibits the migration and invasion of non small cell lung cancer cells via targeting FSCN1. Oncology letters 17 27900045
2023 Targeting FSCN1 with an oral small-molecule inhibitor for treating ocular neovascularization. Journal of translational medicine 16 37596693
2017 MicroRNA‑663 suppresses the proliferation and invasion of colorectal cancer cells by directly targeting FSCN1. Molecular medicine reports 16 29039557
2022 FSCN1 induced PTPRF-dependent tumor microenvironment inflammatory reprogramming promotes lung adenocarcinoma progression via regulating macrophagic glycolysis. Cellular oncology (Dordrecht, Netherlands) 15 36223033
2023 FSCN1 as a new druggable target in adrenocortical carcinoma. International journal of cancer 14 36971100
2023 Switching Rat Resident Macrophages from M1 to M2 Phenotype by Iba1 Silencing Has Analgesic Effects in SNL-Induced Neuropathic Pain. International journal of molecular sciences 14 37958812
2012 Inhibition of SNL-induced upregulation of CGRP and NPY in the spinal cord and dorsal root ganglia by the 5-HT(2A) receptor antagonist ketanserin in rats. Pharmacology, biochemistry, and behavior 14 22342663
2020 N‑Myc induces the tumor progression of prostate cancer by regulating FSCN1. Oncology reports 13 33000273
2018 FSCN1 predicts survival and is regulated by a PI3K-dependent mechanism in renal cell carcinoma. Journal of cellular physiology 13 29148041
2023 SYTL2 promotes metastasis of prostate cancer cells by enhancing FSCN1-mediated pseudopodia formation and invasion. Journal of translational medicine 12 37147713
2022 Long noncoding RNA CDKN2B-AS1 silencing protects against esophageal cancer cell invasion and migration by inactivating the TFAP2A/FSCN1 axis. The Kaohsiung journal of medical sciences 11 36161699
2021 Effect of rs67085638 in long non-coding RNA (CCAT1) on colon cancer chemoresistance to paclitaxel through modulating the microRNA-24-3p and FSCN1. Journal of cellular and molecular medicine 11 33709519
2023 FSCN1 promotes proliferation, invasion and glycolysis via the IRF4/AKT signaling pathway in oral squamous cell carcinoma. BMC oral health 10 37491232
2022 FSCN1 Promotes Glycolysis and Epithelial-Mesenchymal Transition in Prostate Cancer through a YAP/TAZ Signaling Pathway. Evidence-based complementary and alternative medicine : eCAM 10 35815268
2022 DUSP8/TAK1 signaling mediates neuropathic pain through regulating neuroinflammation and neuron death in a spinal nerve ligation (SNL) rat model. International immunopharmacology 10 36279673
2021 FSCN1 Promotes Radiation Resistance in Patients With PIK3CA Gene Alteration. Frontiers in oncology 10 34249689
2021 A novel circ_0099999/miR-330-5p/FSCN1 ceRNA crosstalk in pancreatic cancer. Autoimmunity 10 34409897
2024 ADAM8 silencing suppresses the migration and invasion of fibroblast-like synoviocytes via FSCN1/MAPK cascade in osteoarthritis. Arthritis research & therapy 8 38218854
2025 The Histone Lysine Demethylase KDM7A Contributes to Reward Memory via Fscn1-Induced Synaptic Plasticity in the Medial Prefrontal Cortex. Advanced science (Weinheim, Baden-Wurttemberg, Germany) 7 39836528
2022 MicroRNA-133 suppresses cell viability and migration of rheumatoid arthritis fibroblast-like synoviocytes by down-regulation of MET, EGFR, and FSCN1 expression. Molecular and cellular biochemistry 7 35595956
2021 LncRNA PRNCR1 aggravates the malignancy of oral squamous cell carcinoma by regulating miR-326/FSCN1 axis. European review for medical and pharmacological sciences 7 33928608
2019 Biomarker Analysis of Orally Dosed, Dual Active, Matrix Metalloproteinase (MMP)-2 and MMP-9 Inhibitor, AQU-118, in the Spinal Nerve Ligation (SNL) Rat Model of Neuropathic Pain. International journal of molecular sciences 7 30769782
2009 The chromosomal localization, expression pattern and polymorphism analysis of porcine FSCN1 gene differently expressed from LongSAGE library. Molecular biology reports 7 19688270
2023 The role and regulatory mechanism of FSCN1 in breast tumorigenesis and progression. Yi chuan = Hereditas 6 36927659
2023 LncRNA PTOV1-AS2 Promotes Colon Cancer Progression through the miR-145-5p/FSCN1 Axis. Journal of oncology 6 36960218
2023 Loss of MEG3 contributes to the enhanced migration and invasion in arsenic-induced carcinogenesis through NQO1/FSCN1 pathway. American journal of cancer research 6 37424815
2022 Transcriptome analysis reveals the potential biological function of FSCN1 in HeLa cervical cancer cells. PeerJ 6 35178306
2014 Solanum Nigrum polysaccharide (SNL) extract effects in transplanted tumor-bearing mice--erythrocyte membrane fluidity and blocking of functions. Asian Pacific journal of cancer prevention : APJCP 6 25556494
2024 Targeting MetaLnc9/miR-143/FSCN1 axis inhibits oxidative stress and myofibroblast transdifferentiation in oral submucous fibrosis. Journal of dental sciences 5 39035266
2022 Role of FSCN1 in the tumor microenvironment of lung squamous cell carcinoma. Immunobiology 5 35367835
2022 FSCN1 Promotes Esophageal Carcinoma Progression Through Downregulating PTK6 via its RNA-Binding Protein Effect. Frontiers in pharmacology 5 35401239
2021 WITHDRAWN: Exosomes from microRNA-145-5p-modified HUCB-MSCs attenuate CCl4-induced hepatic fibrosis via down-regulating FSCN1 expression. Life sciences 5 33794251
2020 Long intergenic non-coding RNA 00337 confers progression of esophageal cancer by mediating microrna-145-dependent fscn1. FASEB journal : official publication of the Federation of American Societies for Experimental Biology 5 32654289
2024 N6-methyladenosine methylation on FSCN1 mediated by METTL14/IGF2BP3 contributes to human papillomavirus type 16-infected cervical squamous cell carcinoma. Clinical and experimental pharmacology & physiology 4 38679464
2023 Electroacupuncture inhibits dendritic spine remodeling through the srGAP3-Rac1 signaling pathway in rats with SNL. Biological research 4 37211600
2023 FSCN1 and epithelial mesenchymal transformation transcription factor expression in human pancreatic intraepithelial neoplasia and ductal adenocarcinoma. Pathology, research and practice 4 37832352
2020 Enhanced Suppression of Disulfide Cross-Linking Micelles Nanocarriers Loaded miR-145 Delivering System via Down-Regulation of MYC and FSCN1 in Colon Cancer Cells. Journal of biomedical nanotechnology 4 33397549
2025 The SNL Histone Deacetylase-Binding Factor GmHE13 Is a Novel Regulator of Soybean Hypocotyl Elongation. Plant biotechnology journal 3 40794739
2020 Correction to: The role of microRNA-133b and its target gene FSCN1 in gastric cancer. Journal of experimental & clinical cancer research : CR 3 33081806
2024 The association of FSCN1 (rs852479, rs1640233) and HOTAIR (rs920778) polymorphisms with the risk of breast cancer in Egyptian women. Molecular biology reports 2 38587571
2022 Study on the Function and Mechanism of miR-585-3p Inhibiting the Progression of Ovarian Cancer Cells by Targeting FSCN1 to Block the MAPK Signaling Pathway. Analytical cellular pathology (Amsterdam) 2 35602576
2024 The FSCN1 gene rs2966447 variant is associated with increased serum fascin-1 levels and breast cancer susceptibility. Gene 1 38964493
2024 FSCN1 is a Potential Therapeutic Target for Atherosclerosis Revealed by Single-Cell and Bulk RNA Sequencing. Journal of inflammation research 1 39618922
2023 Comparative proteome and serum analysis identified FSCN1 as a marker of abiraterone resistance in castration-resistant prostate cancer. Prostate cancer and prostatic diseases 1 37634036
2010 Identification and gene mapping of a novel mutant supernumerary lodicules (snl) in rice. Journal of integrative plant biology 1 20377687

Missed literature

Know a paper Affinage missed for FSCN1? Flag it for the maintainers and the community.

No submissions yet.